Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.002
Sell
RSI(14)
42.585
Neutral
STOCH(KDJ)(9,3,3)
22.328
Neutral
ATR(14)
0.055
Low Volatility
CCI(14)
-52.643
Neutral
Williams %R
81.951
Oversold
TRIX(12,20)
-0.742
Sell
StochRSI(14)
76.204
Sell
Search
HCW Biologics Inc
HCWBAdd to Watchlist
1.200USD
+0.863+256.05%
Market hours （ET）Quotes delayed by 15 min
3.15MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of HCW Biologics Inc
Currency: USD Updated: 2026-05-14Key Insights
HCW Biologics Inc's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 187 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 2.00.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
HCW Biologics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
HCW Biologics Inc Highlights
StrengthsRisks
HCW Biologics Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions. It has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a clinical-stage bifunctional molecule that is designed to impact senescence by reducing senescent cells. The Company is prepared to progress HCW9218 in Phase II clinical trials for non-oncology indications.HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, HCW11-006, and others.
Growing
The company is in a growing phase, with the latest annual income totaling USD 54.23K.
Overvalued
The company’s latest PE is -0.03, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 465.64K shares, increasing 39.47% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 0.00 shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.60.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
2.000
Target Price
+472.41%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-14The current financial score of HCW Biologics Inc is 6.44, ranking 240 out of 382 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 27.01K, representing a year-over-year decrease of 93.16%, while its net profit experienced a year-over-year decrease of 2.75%.
Score
Financials
3.82
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.72
Operational Efficiency
3.14
Growth Potential
10.00
Shareholder Returns
7.54
HCW Biologics Inc's Company Valuation
Currency: USD Updated: 2026-05-14The current valuation score of HCW Biologics Inc is 8.93, ranking 4 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.03, which is -39.43% below the recent high of -0.02 and -843287.70% above the recent low of -267.35.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 187/382
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-14The current earnings forecast score of HCW Biologics Inc is 8.00, ranking 159 out of 382 in the Biotechnology & Medical Research industry. The average price target is 35.00, with a high of 35.00 and a low of 35.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
2.000
Target Price
+472.41%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
HCW Biologics Inc
HCWB
1
CRISPR Therapeutics AG
CRSP
29
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Ionis Pharmaceuticals Inc
IONS
25
Beigene Ltd
ONC
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-14The current price momentum score of HCW Biologics Inc is 1.70, ranking 373 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 0.46 and the support level at 0.26, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
0.333
Buy
MA10
0.361
Buy
MA20
0.387
Buy
MA50
0.450
Buy
MA100
0.749
Buy
MA200
2.188
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-14The current institutional shareholding score of HCW Biologics Inc is 3.00, ranking 193 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 6.91%, representing a quarter-over-quarter increase of 49.19%. The largest institutional shareholder is The Vanguard, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-14The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of HCW Biologics Inc is 1.40, ranking 305 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 1.11. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
1.11
VaR
+9.62%
240-Day Maximum Drawdown
+96.53%
240-Day Volatility
+171.00%
Return
Best Daily Return
60 days
+81.19%
120 days
+81.19%
5 years
+320.91%
Worst Daily Return
60 days
-29.90%
120 days
-29.90%
5 years
-29.90%
Sharpe Ratio
60 days
-0.16
120 days
-1.53
5 years
-0.11
Risk Assessment
Maximum Drawdown
240 days
+96.53%
3 years
+99.71%
5 years
+99.87%
Return-to-Drawdown Ratio
240 days
-0.99
3 years
-0.33
5 years
-0.20
Skewness
240 days
+3.73
3 years
+13.56
5 years
+15.56
Volatility
Realised Volatility
240 days
+171.00%
5 years
+170.29%
Standardised True Range
240 days
+86.30%
5 years
+1432.93%
Downside Risk-Adjusted Return
120 days
-309.97%
240 days
-309.97%
Maximum Daily Upside Volatility
60 days
+283.49%
Maximum Daily Downside Volatility
60 days
+144.78%
Liquidity
Average Turnover Rate
60 days
+420.42%
120 days
+213.79%
5 years
--
Turnover Deviation
20 days
-59.56%
60 days
+89.52%
120 days
-3.63%
Peer Comparison
Biotechnology & Medical Research
HCW Biologics Inc
HCWB
5.33 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.66 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.49 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
